Yes, a short course of oral prednisone (40-60 mg/day) is appropriate for an acute Crohn's disease flare while awaiting biologic therapy.
For moderate to severe Crohn's disease, oral prednisone 40-60 mg/day is strongly recommended to induce remission, with treatment duration limited to no more than 8 weeks 1, 2. This approach provides rapid symptom control while biologics are being initiated, which typically take several weeks to achieve therapeutic effect.
Dosing and Duration
- Start prednisone 40-60 mg daily (taken in the morning before 9 am to minimize HPA axis suppression) 1, 3
- Limit duration to ≤8 weeks maximum to reduce adverse effects 2
- Assess response at 2 weeks using clinical symptoms and/or biomarkers (fecal calprotectin) 2
- Begin tapering once biologic takes effect, typically after 2-4 weeks of biologic therapy
Disease Severity Considerations
The appropriateness depends on disease severity:
- Mild ileocecal disease: Consider budesonide 9 mg/day first (fewer side effects, similar efficacy for this location) 1
- Moderate disease that failed budesonide: Use prednisone 40-60 mg/day 1
- Moderate to severe disease: Prednisone 40-60 mg/day is the standard approach 1
Critical Implementation Points
The 2025 British Society of Gastroenterology guidelines emphasize that whenever systemic corticosteroids are prescribed, consideration of initiating or changing advanced therapy (biologics) should occur simultaneously 2. This is precisely your clinical scenario—the steroid course serves as a bridge, not definitive therapy.
Early Assessment is Essential
- Evaluate response at 2 weeks with clinical assessment and biomarkers 2
- If inadequate response, escalate therapy rather than continuing steroids 2
- Avoid repeated steroid courses—if a second course is needed within 12 months, this indicates need for biologic therapy or therapy optimization 2
Common Pitfalls to Avoid
Do not use steroids for maintenance therapy—strong recommendation against this in all guidelines 1. Steroids are for induction only.
Do not taper too rapidly—this increases relapse risk. However, also avoid prolonging beyond 8 weeks due to cumulative toxicity 2.
Do not delay biologic initiation—the steroid is a bridge therapy. The 2025 guidelines specifically advocate for early advanced therapy in moderate to severe disease 2, 4.
Monitor for steroid-related complications: infection risk (including TB reactivation, fungal infections), hyperglycemia, hypertension, and psychiatric effects 3.
Biologic Timing Considerations
While steroids provide symptom relief, biologics should be initiated concurrently or as soon as possible 4. The Canadian guidelines note that patients with moderate to severe CD with poor prognostic factors should receive anti-TNF therapy as first-line treatment 1, suggesting that in some cases, biologics could be started without steroids if the wait time is short.
Steroid-Sparing Strategy
If the biologic injection is delayed beyond 2-4 weeks:
- Continue monitoring response every 2 weeks 2
- Consider adding immunomodulator (azathioprine/6-MP) if steroid dependency develops, though this is less relevant for short-term bridging 1
- Reassess need for hospitalization if symptoms worsen despite steroids 1
Evidence Quality Note
The recommendation for prednisone in moderate-severe CD carries a strong recommendation despite low-quality evidence 1, reflecting decades of clinical experience showing consistent efficacy. The 2025 BSG guidelines rate the overall certainty as moderate with conditional recommendation 2, emphasizing the balance between efficacy and adverse effects.
The key principle: Use steroids as a short-term bridge to biologic therapy, not as standalone treatment, with early assessment to ensure timely escalation if needed 2.